Thoroughbred Financial Services LLC Takes Position in argenx SE (NASDAQ:ARGX)

Thoroughbred Financial Services LLC acquired a new position in argenx SE (NASDAQ:ARGX) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 1,208 shares of the company’s stock, valued at approximately $742,000.

Several other large investors also recently added to or reduced their stakes in the business. Whipplewood Advisors LLC bought a new position in argenx in the fourth quarter worth approximately $37,000. Global Retirement Partners LLC increased its stake in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after purchasing an additional 61 shares during the period. Huntington National Bank lifted its position in argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company’s stock valued at $46,000 after purchasing an additional 68 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after purchasing an additional 33 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Piper Sandler lifted their price target on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Finally, Citigroup reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Stock Down 5.9 %

NASDAQ ARGX opened at $555.11 on Friday. The firm has a market capitalization of $33.73 billion, a price-to-earnings ratio of -630.81 and a beta of 0.60. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a fifty day moving average of $621.43 and a two-hundred day moving average of $603.18.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. Equities research analysts anticipate that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.